Skip to main content
SpringerLink
Log in

Drug Treatment of Depression in HIV-Positive Patients

Safety Considerations

  • Practical Drug Safety
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Safe and effective treatment of major depression, one of the most common comorbid conditions in individuals infected with HIV, significantly lowers morbidity and mortality from HIV disease. However, optimal treatment of both conditions is complicated by interactions between the disease processes as well as the pharmacological agents used to treat them. In patients with HIV it may be difficult to distinguish major depression from other physiological and emotional states that present with similar symptoms. Accurate diagnosis of major depression is thus complex and essential to preventing inappropriate exposure of patients to potentially harmful psychotropic medications. This review outlines important initial steps in making this diagnosis. All patients with HIV should be screened for depression by their medical providers and referred to a psychiatrist for full evaluation when necessary. The mainstay of treatment for major depression in patients with HIV disease is pharmacotherapy. Depressed patients with HIV respond to the same wide variety of antidepressant-class medications as depressed patients without HIV, including tricyclic antidepressants, paroxetine, fluoxetine and trazodone. Notably, new studies have also shown that some psychiatric medications can inhibit HIV replication.

No particular antidepressant medication is superior for the treatment of depressed HIV-infected patients; however, the most important component of treatment of major depression in HIV-disease is patient adherence, which is highly influenced by antidepressant adverse effects. This review outlines adverse effects of antidepressant-class medications that are of particular concern in HIV-infected patients and describes pharmacological strategies for overcoming these potential barriers to medication adherence. This review also describes situations in which some adverse effects of antidepressant-class medications may be safely exploited to benefit depressed patients with HIV disease. Potential interactions between antidepressant-class medications and HIV medications, as well as pharmacological treatment strategies for treating the psychiatric adverse effects of HIV medications, are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58: 721–8

    Article  PubMed  CAS  Google Scholar 

  2. Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54Suppl. 1: S22–8

    Article  PubMed  Google Scholar 

  3. Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS 1996; 10: 1033–9

    Article  PubMed  CAS  Google Scholar 

  4. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725–30

    Article  PubMed  CAS  Google Scholar 

  5. Dew MA, Becket JT, Sanchez J, et al. Prevalence and predictors of depressive, anxiety and substance use disorders in HIV infected and uninfected men: a longitudinal evaluation. Psychol Med 1997; 27: 395–409

    Article  PubMed  CAS  Google Scholar 

  6. Dimatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 2000; 160: 2101–7

    Article  PubMed  CAS  Google Scholar 

  7. Lenz G, Demal U. Quality of life in depression and anxiety disorders: an exploratory follow-up after intensive cognitive-behavior therapy. Psychopathology 2000; 33: 297–302

    Article  PubMed  CAS  Google Scholar 

  8. Meltzer-Brody S, Davidson JR. Completeness of response and quality of life in mood and anxiety disorders. Depress Anxiety 2000; 12Suppl. 1: 95–101

    Article  PubMed  Google Scholar 

  9. Holmes J, House A. Psychiatric illness predicts poor outcome after surgery for hip fracture: a prospective cohort study. Psychol Med 2000; 30: 921–9

    Article  PubMed  CAS  Google Scholar 

  10. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8: 261–9

    Article  PubMed  CAS  Google Scholar 

  11. Hays RD, Kravitz RL, Mazel RM, et al. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. J Behav Med 1994; 14: 88–90

    Google Scholar 

  12. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1446–74

    Article  Google Scholar 

  13. Leserman J, Jackson ED, Petitto JM, et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med 1999; 61: 397–406

    PubMed  CAS  Google Scholar 

  14. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003; 54: 295–306

    Article  PubMed  Google Scholar 

  15. Stein MD, Solomon DA, Herman DS, et al. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry 2003; 160: 1659–62

    Article  PubMed  Google Scholar 

  16. Riley ED, Wu AW, Perry S, et al. Depression and drug use impact health status among marginally housed HIV-infected individuals. AIDS Patient Care STDS 2003; 17(8): 401–6

    Article  PubMed  Google Scholar 

  17. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA 2001; 285(11): 1466–74

    Article  PubMed  CAS  Google Scholar 

  18. van Servellen G, Chang B, Garcia L, et al. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 2002; 16(6): 269–81

    Article  PubMed  Google Scholar 

  19. Tresiman GJ. AIDS education for psychiatrists. Prim Psychiatry 1999; 6: 71–3

    Google Scholar 

  20. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav 2003; 7(2): 101–8

    Article  PubMed  Google Scholar 

  21. Treisman G, Fishman M, Schwartz J, et al. Mood disorders in HIV infection. Depress Anxiety 1998; 7(4): 178–87

    Article  PubMed  CAS  Google Scholar 

  22. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001 Sep 15; 33(6): 847–56

    Article  PubMed  CAS  Google Scholar 

  23. Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs 1999; 58: 1099–135

    Article  PubMed  CAS  Google Scholar 

  24. Rachlis A, Fanning MM. Zidovudine toxicity: clinical features and management. Drug Saf 1993; 8: 312–20

    Article  PubMed  CAS  Google Scholar 

  25. Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101: 34–40

    Article  PubMed  CAS  Google Scholar 

  26. McDaniel JS, Purcell DW, Farber EW. Severe mental illness and HIV-related medical and neuropsychiatric sequelae. Clin Psychol Rev 1997; 17: 311–25

    Article  PubMed  CAS  Google Scholar 

  27. Lyketsos CJ, Fishman M, Hutton H, et al. The effectiveness of psychiatric treatment for HIV-infected patients. Psychosomatics 1997; 38: 423–32

    Article  PubMed  CAS  Google Scholar 

  28. Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 1996; 153(11): 1430–7

    PubMed  CAS  Google Scholar 

  29. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry 2002; 24: 43–7

    Article  PubMed  Google Scholar 

  30. Katon W. The epidemiology of depression in medical care. Int J Psychiatry Med 1987; 17: 93–112

    Article  PubMed  CAS  Google Scholar 

  31. Schulberg HC, Block MR, Madonia MJ, et al. The usual care of major depression in primary care practice. Arch Fam Med 1997; 6: 334–9

    Article  PubMed  CAS  Google Scholar 

  32. Perez-Stable E, Miranda J, Munoz R, et al. Depression in medical outpatients: under-recognition and misdiagnosis. Arch Intern Med 1990; 150: 1083–8

    Article  PubMed  CAS  Google Scholar 

  33. Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med 2003; 18(6): 450–60

    Article  PubMed  Google Scholar 

  34. Perkins DO, Leserman J, Stern RA, et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry 1995; 155(12): 1776–81

    Google Scholar 

  35. Pugh K, Riccio M, Jadresic D, et al. A longitudinal study of the neuropsychiatry consequences of HIV-1 infection in gay men. II: Psychological and health status at baseline and at 12-month follow-up. Psychol Med 1994; 24: 897–904

    Article  PubMed  CAS  Google Scholar 

  36. Lyketsos CG, Hanson A, Fishman M, et al. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med 1994; 24: 103–13

    Article  PubMed  CAS  Google Scholar 

  37. Treisman G, Fishman M, Lyketsos C, et al. Evaluation and treatment of psychiatric disorders associated with HIV infection. Res Publ Assoc Res Nerv Ment Dis 1994; 72: 239–50

    PubMed  CAS  Google Scholar 

  38. Lyketsos CG, Treisman GJ. Psychiatric disorders in HIV-infected patients. CNS Drugs 1995; 4: 195–206

    Article  Google Scholar 

  39. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994; 151: 516–23

    PubMed  CAS  Google Scholar 

  40. Grassi B, Gambini O, Garghentini G, et al. Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Pharmacopsychiatry 1997; 30(2): 70–1

    Article  PubMed  CAS  Google Scholar 

  41. Cazzullo CL, Bessone E, Bertrando P, et al. Treatment of depression in HIV-infected patients. J Psychiatry Neurosci 1998; 23(5): 293–7

    PubMed  CAS  Google Scholar 

  42. De Wit S, Cremers L, Hirsch D, et al. Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res 1999; 27(5): 223–32

    PubMed  Google Scholar 

  43. Kristiansen JE, Hansen JB. Inhibition of HIV replication by neuroleptics agents and their potential use in HIV infected patients with AIDS related dementia. Int J Antimicrob Agents 2000; 14(3): 209–13

    Article  PubMed  CAS  Google Scholar 

  44. Treisman GJ, Angelino AF. The Psychiatry of AIDS: a guide to diagnosis and treatment. Chapter 2: HIV and major depression. Baltimore (MD): The Johns Hopkins University Press, 2004

    Google Scholar 

  45. Elliott AJ, Uldall KK, Bergam K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive patients. Am J Psychiatry 1998; 155(3): 367–72

    PubMed  CAS  Google Scholar 

  46. Zisook S, Peterkin J, Goggin KJ, et al. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998; 59(5): 217–24

    Article  PubMed  CAS  Google Scholar 

  47. Rabkin JG, Wagner G, et al. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999; 156: 101–7

    PubMed  CAS  Google Scholar 

  48. Rabkin JG, Wagner G, Rabkin R. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry 1994; 55: 92–7

    PubMed  CAS  Google Scholar 

  49. Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry 1994; 55: 433–9

    PubMed  CAS  Google Scholar 

  50. Ferrando SJ, Rabkin JG, deMoore GM, et al. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry 1999; 60: 741–6

    Article  PubMed  CAS  Google Scholar 

  51. Rothschild AJ. New directions in the treatment of antidepressant-induced sexual dysfunction. Clin Ther 2000; 22Suppl. A: A42–A51; discussion A58-61

    Article  PubMed  CAS  Google Scholar 

  52. Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. Ann Pharmacother 1998; 32: 1209–15

    Article  PubMed  CAS  Google Scholar 

  53. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997; 16(6): 374–90

    Article  PubMed  CAS  Google Scholar 

  54. Younai FS, Marcus M, Freed JR, et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 629–36

    Article  PubMed  CAS  Google Scholar 

  55. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: improvement in affective and somatic symptoms. Gen Hosp Psychiatry 1997; 19: 89–97

    Article  PubMed  CAS  Google Scholar 

  56. Elliott AJ, Russo J, Bergam K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999; 60: 226–31

    Article  PubMed  CAS  Google Scholar 

  57. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000; 20: 265–7

    Article  PubMed  CAS  Google Scholar 

  58. Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001; 29: 100–2

    PubMed  CAS  Google Scholar 

  59. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003; 17: 638–40

    Article  PubMed  Google Scholar 

  60. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry 1995; 25: 53–67

    Article  CAS  Google Scholar 

  61. Wagner GJ, Rabkin JG, Rabkin R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997; 42: 407–11

    Article  PubMed  CAS  Google Scholar 

  62. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61: 436–40

    Article  PubMed  CAS  Google Scholar 

  63. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psych 1983; 40: 1335–42

    Article  CAS  Google Scholar 

  64. Neirenberg AA, Price LH, Charney DS, et al. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990; 18: 167–75

    Article  Google Scholar 

  65. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634–40

    Article  PubMed  CAS  Google Scholar 

  66. Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–6

    Article  PubMed  CAS  Google Scholar 

  67. Ogura C, Okuma T, Uchida Y, et al. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974; 28: 179–86

    PubMed  CAS  Google Scholar 

  68. Joffe RT, Levitt AJ, Bagby M, et al. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993; 163: 574–8

    Article  PubMed  CAS  Google Scholar 

  69. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–4

    Article  PubMed  CAS  Google Scholar 

  70. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997; 154: 37–43

    PubMed  CAS  Google Scholar 

  71. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16–21

    Article  PubMed  CAS  Google Scholar 

  72. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://hivatis.org [Accessed 2001 Jan 1]

  73. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381–90

    Article  PubMed  CAS  Google Scholar 

  74. Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999; 33: 461–73

    Article  PubMed  CAS  Google Scholar 

  75. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2003; 16: 1201–15

    Article  Google Scholar 

  76. Dresser GK, Spence JD, Bailey DG. Pharmocokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41–57

    Article  PubMed  CAS  Google Scholar 

  77. Ouellet D, Hsu A, Qian J, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42(12): 3107–12

    PubMed  CAS  Google Scholar 

  78. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25(4): 1200–10

    Article  PubMed  CAS  Google Scholar 

  79. DeSilva KE, LeFlore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15: 1281–5

    Article  PubMed  CAS  Google Scholar 

  80. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43(4): 414–22

    Article  PubMed  CAS  Google Scholar 

  81. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections: studies with neuropsychologic testing and magnetic resonance imaging [published erratum appears in Ann Intern Med 1988, 108 (3): 496]. Ann Intern Med 1987; 107: 828–36

    PubMed  CAS  Google Scholar 

  82. Van Gorp WG, Satz P, Hinkin C, et al. The neuropsychological aspects of HIV-1 spectrum disease. Psychiatr Med 1989; 7: 59–78

    PubMed  Google Scholar 

  83. McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virus-associated dementia. Semin Neurol 1999; 19: 129–50

    Article  PubMed  CAS  Google Scholar 

  84. Low-Beer S, Chan K, Yip B, et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000; 23: 295–301

    PubMed  CAS  Google Scholar 

  85. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl J Med 1987; 317: 185–91

    Article  PubMed  CAS  Google Scholar 

  86. Blum MR, Liao SH, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85: 189–94

    Article  PubMed  CAS  Google Scholar 

  87. Maxwell S, Scheftner WA, Kessler HA. Manic syndrome associated with zidovudine treatment [letter]. JAMA 1988; 259: 3406–7

    Article  PubMed  CAS  Google Scholar 

  88. Wright JM, Sachdev PS, Perkins RJ, et al. Zidovudine-related mania. Med J Aust 1989; 150: 339–41

    PubMed  CAS  Google Scholar 

  89. O’Dowd MA, McKegney FP. Manic syndrome associated with zidovudine [letter]. JAMA 1988; 260: 3587–8

    Article  Google Scholar 

  90. SUSTIVATM (efavirenz) capsules [US prescribing information]. Wilmington (DE): DuPont Pharmaceuticals Company, 2000

  91. Colebunders R, Verdonck K. Reply to Gonzalex and Everall. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs [letter]. AIDS 1999; 13: 869

    Article  PubMed  CAS  Google Scholar 

  92. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865–73

    Article  PubMed  CAS  Google Scholar 

  93. Moyle G. Efavirenz: practicalities, considerations and new issues. Int J Clin Pract Suppl 1999; 103: 30–4

    PubMed  CAS  Google Scholar 

  94. Hawkins T, Grossman D, Haubrich R. CNS side effects of EFV may persist in patients thought to tolerate the drug [abstract WePpB1376]. XIII International Conference on AIDS; 2000 Jul 9-14; Durban.

  95. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The patient care that was the basis for this article was supported by Ryan White Title I and Ryan White Title II funding. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    Andrew A. Pieper

  2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, Maryland, 21287-7413, USA

    Glenn J. Treisman

Authors
  1. Andrew A. Pieper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glenn J. Treisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenn J. Treisman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pieper, A.A., Treisman, G.J. Drug Treatment of Depression in HIV-Positive Patients. Drug-Safety 28, 753–762 (2005). https://doi.org/10.2165/00002018-200528090-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200528090-00002

Keywords

Search

Navigation